Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Artia Global Partners LP

Q3 2023 · 13F-HR

Artia Global Partners LPholdings as filed

Filed 2023-11-14 · accession 0001937964-23-000006

$240.6M
Reported value
27
Positions
2023-09-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
670100205NVONOVO-NORDISK A S$62.0M25.8%681,812CommonSOLE
58933Y105MRKMERCK & CO INC$33.9M14.1%329,200CommonSOLE
04016X101ARGXARGENX SE$24.2M10.1%49,238CommonSOLE
532457108LLYLILLY ELI & CO$14.1M5.85%26,193CommonSOLE
00287Y109ABBVABBVIE INC$13.5M5.63%90,821CommonSOLE
046353108AZNNASTRAZENECA PLC$12.9M5.37%190,752CommonSOLE
81181C104SEAGEN INC$10.9M4.51%51,175CommonSOLE
G76279101ROIVROIVANT SCIENCES LTD$10.7M4.44%914,023CommonSOLE
282559103ETNBGBP89BIO INC$7.2M2.99%465,465CommonSOLE
09061G101BMRNBIOMARIN PHARMACEUTICAL INC$6.9M2.89%78,465CommonSOLE
803607100SRPTSAREPTA THERAPEUTICS INC$6.9M2.88%57,162CommonSOLE
92532F100VRTXVERTEX PHARMACEUTICALS INC$6.4M2.65%18,314CommonSOLE
05464T104AXSMAXSOME THERAPEUTICS INC$6.1M2.55%87,848CommonSOLE
64125C109NBIXNEUROCRINE BIOSCIENCES INC$5.1M2.10%45,000CommonSOLE
92686J106VKTXVIKING THERAPEUTICS INC$4.2M1.77%383,580CommonSOLE
02043Q107ALNYALNYLAM PHARMACEUTICALS INC$2.8M1.18%15,971CommonSOLE
46116X101ITCIEURINTRA-CELLULAR THERAPIES INC$2.2M0.90%41,600CommonSOLE
92243G108PCVXVAXCYTE INC$2.0M0.82%38,555CommonSOLE
74366E102PTGXPROTAGONIST THERAPEUTICS INC$1.9M0.78%112,340CommonSOLE
729139105PLRXPLIANT THERAPEUTICS INC$1.7M0.72%100,000CommonSOLE
159864107CRLCHARLES RIV LABS INTL INC$1.4M0.56%6,905CommonSOLE
883556102TMOTHERMO FISHER SCIENTIFIC INC$1.1M0.44%2,109CommonSOLE
941848103WATWATERS CORP$780,1270.32%2,845CommonSOLE
90240B106TYRATYRA BIOSCIENCES INC$623,1340.26%45,253CommonSOLE
23257D103CBAYUSDCYMABAY THERAPEUTICS INC$615,2020.26%41,261CommonSOLE
09077A106BMEABIOMEA FUSION INC$350,2200.15%25,452CommonSOLE
39868T1052JQGRITSTONE BIO INC$163,6920.07%95,170CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.